Detailed Instructions: Indicate the presence of numerical data in the abstract (whether numerical data plays a key role in medical records), solely using the information from the abstract.
See one example below:
Problem: Abstract: Some patients converted from ventricular fibrillation to organized rhythms by defibrillation - trained ambulance technicians(EMT - Ds) will refibrillate before hospital arrival.The authors analyzed 271 cases of ventricular fibrillation managed by EMT - Ds working without paramedic back - up.Of 111 patients initially converted to organized rhythms, 19(17%) refibrillated, 11(58%) of whom were reconverted to perfusing rhythms, including nine of 11(82%) who had spontaneous pulses prior to refibrillation.Among patients initially converted to organized rhythms, hospital admission rates were lower for patients who refibrillated than for patients who did not(53 % versus 76% , P = NS), although discharge rates were virtually identical(37 % and 35 % , respectively).Scene - to - hospital transport times were not predictively associated with either the frequency of refibrillation or patient outcome.Defibrillation - trained EMTs can effectively manage refibrillation with additional shocks and are not at a significant disadvantage when paramedic back - up is not available.
Question: Does the abstract contain any numerical data?
Solution: Yes
Explanation: As there are numerical figures and percentages (%), the answer is yes.

Problem: Abstract: Although increased efficacy has been described with a five-day schedule of high-dose cisplatin (CDDP) in hypertonic saline, severe myelosuppression and cumulative neurotoxicity have limited the usefulness of this therapy. In order to evaluate a possible dose-response relationship in non-small-cell lung cancer (NSCLC), 17 patients with metastatic disease were treated with a modified dose schedule delivering the same total dose (200 mg/m2) in a divided day 1 and 8 schedule. During a pilot study, a total of 47 cycles of therapy were administered, with a median of three cycles per patient and a median total cumulative dose of 600 mg/m2. Nine of 17 patients received at least 600 mg/m2. While nephrotoxicity was similar to previous reports of the five-day schedule, the incidence and severity of myelosuppression and peripheral neuropathy were markedly reduced. Using this modified schedule, severe myelosuppression did not occur. Clinically severe peripheral neuropathy developed in only one patient (6%). The overall response rate was 47% (eight of 17 patients). Plasma platinum pharmacokinetics during five cycles of the modified day 1 and 8 schedule were compared with pharmacokinetics of the five-day schedule. Accumulation of plasma ultrafiltrate platinum occurred in the five-day schedule, but not in the day 1 and 8 schedule. This difference in pharmacokinetics is one possible explanation for the reduced toxicity of this modified schedule. Although the degree of activity seen in this pilot study is encouraging, the efficacy of high-dose CDDP in NSCLC remains to be defined. In view of reduced myelosuppression and neurotoxicity, further trials with this modified schedule are indicated.
Question: Does the abstract contain any numerical data?
Solution:
Yes